<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03490097</url>
  </required_header>
  <id_info>
    <org_study_id>PHCL35</org_study_id>
    <nct_id>NCT03490097</nct_id>
  </id_info>
  <brief_title>Statins in Chronic Hepatitis C Patients Receiving Sofosbuvir/Daclatasvir/Ribavirin Combination</brief_title>
  <official_title>Benefits of Statins in Chronic Hepatitis C Patients Receiving Sofosbuvir/Daclatasvir/Ribavirin Combination</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ain Shams University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ain Shams University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to determine if statin can affect the clinical outcome of chronic
      hepatitis C patients receiving Sofosbuvir/Daclatasvir/Ribavirin combination
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Aim of the work

      To determine the benefits of statin use in CHC patients treated with
      Sofosbuvir/Daclatasvir/Ribavirin through :

      Primary Outcome: Assessment of therapeutic SVR12

      Seconadry Outcome

      1. assessment of Chronic hepatitis C(CHC) infection risk on development of metabolic syndrome
      through assessment of lipid profile , fasting glucose test , HgbA1C and C-reactive
      protein(CRP).

      2- Evaluation of CHC related complications such as fibrosis and cirrhosis

      Patients will be followed up for the whole study period and will be subjected to assessment
      of the following:

        1. CBC , liver function test , lipid profile and CK every month till the end of therapy.

        2. HgA1C and CRP at the end of therapy.

        3. HCV-PCR test 3 months after the end of therapy.

        4. Fibrosis using (FIB-4) 3 months after the end of therapy.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 1, 2017</start_date>
  <completion_date type="Anticipated">May 2018</completion_date>
  <primary_completion_date type="Anticipated">May 2018</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>SVR 12</measure>
    <time_frame>3 months after end of therapy</time_frame>
    <description>sustained virological response 3 months after the end of therapy</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Lipid marker</measure>
    <time_frame>three months</time_frame>
    <description>lipid profile</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Glycemic status marker</measure>
    <time_frame>three months</time_frame>
    <description>fasting glucose test</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>inflammatory marker</measure>
    <time_frame>three months</time_frame>
    <description>C-reactive protein(CRP).</description>
  </secondary_outcome>
  <other_outcome>
    <measure>CHC related complications</measure>
    <time_frame>6 months</time_frame>
    <description>fibrosis and cirrhosis</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Chronic Hepatitis c</condition>
  <condition>Metabolic Syndrome</condition>
  <arm_group>
    <arm_group_label>Group I</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>low dose of simvastatin10 mg plus sofosbuvir 400mg / daclatasvir 60 mg / ribavirin 1000 mg for patients&lt;75kg and 1200mg for patients &gt;75kg daily for 12 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group II</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>sofosbuvir plus daclatasvir plus ribavirin</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Simvastatin 10mg</intervention_name>
    <description>tablets</description>
    <arm_group_label>Group I</arm_group_label>
    <other_name>simvastatin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>sofosbuvir plus daclatasvir plus ribavirin</intervention_name>
    <description>sofosbuvir 400mg daclatasvir 60 mg / ribavirin 1000 mg for patients&lt;75kg and 1200mg for patients &gt;75kg daily for 12 weeks.</description>
    <arm_group_label>Group I</arm_group_label>
    <arm_group_label>Group II</arm_group_label>
    <other_name>Sovodac plus ribavirin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male patients age 18 to 70 years old.

          2. Easy to treat group: treatment naïve patients with serum HCV RNA positivity by PCR.

          3. Clinically stable condition outpatients.

          4. Platelet count ≥ 150,000/mm³.

          5. INR ≤ 1.2.

          6. Serum albumin ≥ 3.5 g/dl.

          7. Total serum bilirubin ≤ 1.2 mg/dl.

        Exclusion Criteria:

          1. Inadequately controlled diabetes mellitus (HbA1c &gt; 9%) .

          2. Total serum bilirubin &gt; 3mg/dl.

          3. HCV-HIV co infection.

          4. HBV-HCV co infection.

          5. Any cause for chronic liver disease other than hepatitis C

          6. Uncontrolled hypothyroidism.

          7. Hepatocellular carcinoma, except 4 weeks after intervention aiming at cure with no
             evidence of activity by dynamic imaging (CT or MRI).

          8. Extra-hepatic malignancy except after two years of disease-free interval.

          9. Child's C cirrhotic patients.

         10. Creatinine kinase &gt; 350 u/l
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nagwa Ali Sabri, Professor</last_name>
    <role>Study Director</role>
    <affiliation>Professor of clinical pharmacy , ASU</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sara Mahmoud Shaheen, phD</last_name>
    <phone>00201008742248</phone>
    <email>drsara61181@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Nagwa Ali Sabri, Professor</last_name>
    <phone>00201223411984</phone>
    <email>nagwa.sabri@yahoo.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Kobri El koba Armed Forces Hospital</name>
      <address>
        <city>Cairo</city>
        <country>Egypt</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hossam Zakarya, Bsc</last_name>
      <phone>00201117175556</phone>
      <email>dr.hossamz@yahoo.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 19, 2018</study_first_submitted>
  <study_first_submitted_qc>March 30, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">April 6, 2018</study_first_posted>
  <last_update_submitted>March 30, 2018</last_update_submitted>
  <last_update_submitted_qc>March 30, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 6, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Ain Shams University</investigator_affiliation>
    <investigator_full_name>Sara Mahmoud Shaheen</investigator_full_name>
    <investigator_title>Associate Professor, Faculty of pharmacy, Ain Shams University</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
    <mesh_term>Hepatitis, Chronic</mesh_term>
    <mesh_term>Metabolic Syndrome X</mesh_term>
    <mesh_term>Hepatitis C, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ribavirin</mesh_term>
    <mesh_term>Simvastatin</mesh_term>
    <mesh_term>Sofosbuvir</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

